Brief: Oncosec Collaborates With Providence Cancer Institute To Conduct First-In-Human Trial Of Oncosec's Corvax12
06/04/2020 14:28
April 6 (Reuters) - OncoSec Medical Inc ONCS.O :
* ONCOSEC COLLABORATES WITH PROVIDENCE CANCER INSTITUTE TO
CONDUCT
FIRST-IN-HUMAN TRIAL OF ONCOSEC'S CORVAX12, AN INVESTIGATIONAL
VACCINE TO PREVENT COVID-19, COMBINING AN ENHANCED "SPIKE" DNA
SEQUENCE AND TAVO™
* ONCOSEC MEDICAL INC - PROVIDENCE SUBMITS INVESTIGATOR
INITIATED
IND WITH CORVAX12 FOR A PHASE 1 CLINICAL TRIAL
Source text for Eikon: ID:nPn3kYll3a
Further company coverage: ONCS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OncoSec Medical Incorporated
See all newsBrief: OncoSec Medical Inc On June 15 Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
U.S. STOCKS ON THE MOVE-Domino's, Aldeyra, MicroVision
Brief: OncoSec Medical Files Voluntary Petition For Relief Under Provisions Of Chapter 7 Of Title 11 Of United States Code
Brief: OncoSec Medical Terminates George Chi For Cause As Employee, CFO
Brief: Oncosec Medical Receives Non Compliance Notice From Nasdaq